Search

155 Result(s)
Sort by

Learning and development

Learning and development

We help people grow professionally by maximizing our talent and giving them room to evolve within the company.
Alexander Guntur

Alexander Guntur

Alexander Guntur, Information Protection and Security officer in Singapore, describes his 14 years with the company as fulfilling.
Andreas Lenk

Andreas Lenk

Andreas Lenk, Head of Legal and Compliance Germany, discusses his role supporting human pharma and animal health business in legal and compliance matters.
Ethics and Compliance

Ethics and Compliance

Consistent with the Core of our Leitbild and Code of Conduct, we act with integrity and are committed to conducting business in a lawful and ethical manner.
Anna Mezentseva

Anna Mezentseva

Anna Mezentseva talks about being a discovery management trainee in Finance and Controlling.
EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney disease

EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice 1,2,3 Phase III trial also demonstrated a 14% statistically significant reduction
Irene Anindita

Irene Anindita

Irene Anindita is a Multichannel Manager for Cardiovascular and Metabolism Team in Amsterdam, the Netherlands, and really loves the vibe.
Christina Schmitt

Christina Schmitt

Christina Schmitt loves that she can be creative every day as a biopharma management trainee at Boehringer Ingelheim.
Daniel Kiesenhofer

Daniel Kiesenhofer

Daniel Kiesenhofer talks about his role as Project Manager Quality Control at Boehringer Ingelheim in Vienna, Austria.
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis 

Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis 

Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer